UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON
, D.C. 20549
FORM
10-QSB
Amendment
Number 1
T
|
Quarterly
report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934
|
For
the
quarterly period ended September 30, 2007
£
|
Transition
Report under Section 13 or 15(d) of the Securities Exchange Act
of 1934
for the transition period from ___ to ___
|
Commission
file number: 000-3188 3
PROTON
LABORATORIES,
INC.
(NAME
OF
SMALL BUSINESS ISSUER IN ITS CHARTER)
Washington
|
91-2022700
|
(State
or other jurisdiction of incorporation or organization)
|
(
IRS Employer Identification No.)
|
980
Atlantic Avenue, Suite 110
Alameda,
CA 94501
(Address
of principal executive
offices)
(510)
865-6412
Issuer's
telephone number
Check
whether the Issuer (1) filed all reports required to be filed by Section
13 or
15(d) of the Securities Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and
(2)
has been subject to such filing requirements for the past 90 days. Yes T No
£
Indicate
by check whether the registrant is a shell company (as defined in Rule 12b-2
of
the Exchange Act). Yes £ No
T
On
November 8, 2007 , the registrant had outstanding 29,470,523 Common Stock,
$0.0001 par value per share.
Transitional
Small Business Disclosure Format: Yes £ No
T
Introduction:
This
amendment
number 1 provides new Part 1-Item 3—Controls and Procedures, new certifications
for exhibits 31.1 and 31.2, and the current company address on the cover
page.
|
|
|
PAGE
|
|
|
|
|
|
|
|
|
|
|
|
|
PART
I -
|
FINANCIAL
INFORMATION.
|
3
|
|
|
|
|
ITEM
1.
|
|
3
|
|
|
|
|
|
3
|
|
|
|
|
|
4
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
6
|
|
|
|
|
|
|
|
|
ITEM
2.
|
|
10
|
|
|
|
|
|
12
|
|
|
12
|
|
Risk
Factors
|
13
|
|
|
|
|
|
|
|
|
ITEM
3.
|
|
13
|
|
|
|
|
PART
II -
|
OTHER
INFORMATION
|
14
|
|
|
|
|
ITEM
1.
|
|
14
|
|
|
|
|
ITEM
2.
|
|
14
|
|
|
|
|
ITEM
3.
|
|
14
|
|
|
|
|
ITEM
4.
|
|
14
|
|
|
|
|
ITEM
5.
|
|
15
|
|
|
|
|
ITEM
6.
|
|
15
|
|
|
|
|
|
16
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
|
|
SEPTEMBER 30,
|
|
|
DECEMBER 31,
|
|
|
|
2007
|
|
|
2006
|
|
ASSETS
|
|
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
ASSETS
|
|
|
|
|
|
|
Cash
|
|
$ |
8,461 |
|
|
$ |
9,768 |
|
Accounts
receivable, less allowance for doubtful accounts of 24,586 and
$30,419, respectively
|
|
|
2,403 |
|
|
|
794 |
|
Inventory
|
|
|
113,652 |
|
|
|
143,865 |
|
TOTAL
CURRENT ASSETS
|
|
|
124,516 |
|
|
|
154,427 |
|
PROPERTY
AND EQUIPMENT
|
|
|
|
|
|
|
|
|
Furniture
and fixtures
|
|
|
23,316 |
|
|
|
23,316 |
|
Equipment
and machinery
|
|
|
241,680 |
|
|
|
238,776 |
|
Leasehold
improvements
|
|
|
15,823 |
|
|
|
11,323 |
|
Accumulated
depreciation
|
|
|
(99,270 |
)
|
|
|
(69,550 |
)
|
NET
PROPERTY
AND EQUIPMENT
|
|
|
181,549 |
|
|
|
203,865 |
|
DEPOSITS
|
|
|
6,131 |
|
|
|
6,131 |
|
TOTAL
ASSETS
|
|
$ |
312,196 |
|
|
$ |
364,423 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' DEFICIT
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$ |
126,789 |
|
|
|
71,314 |
|
Accrued
expenses
|
|
|
331,801 |
|
|
|
266,079 |
|
Deferred
revenue
|
|
|
52,506 |
|
|
|
52,506 |
|
Preferred
dividends payable
|
|
|
20,800 |
|
|
|
16,000 |
|
Convertible
debenture, net discount of $141,507
|
|
|
108,493 |
|
|
|
- |
|
Fair
value of derivative liabilities
|
|
|
361,148 |
|
|
|
- |
|
TOTAL
CURRENT LIABILITIES
|
|
|
1,001,537 |
|
|
|
405,899 |
|
STOCKHOLDER
LOANS
|
|
|
307,642 |
|
|
|
270,642 |
|
TOTAL
LIABILITIES
|
|
|
1,309,179 |
|
|
|
676,541 |
|
STOCKHOLDERS'
DEFICIT
|
|
|
|
|
|
|
|
|
Series
A convertible preferred stock, 400,000 shares authorized with a par
value of $0.0001; 8,000 shares issued and outstanding; liquidation
preference of $80,000 and $0, respectively
|
|
|
80,000 |
|
|
|
80,000 |
|
Undesignated
preferred stock, 19,600,000 shares authorized with a par value of
$0.0001; no shares issued or outstanding
|
|
|
- |
|
|
|
- |
|
Common
stock, 100,000,000 common shares authorized with a par value of
$0.0001; 29,270,523 and 21,658,223 shares issued and outstanding,
respectively
|
|
|
2,929 |
|
|
|
2,168 |
|
Additional
paid in capital
|
|
|
5,892,162 |
|
|
|
4,045,371 |
|
Stock
subscription receivable
|
|
|
(20,000 |
)
|
|
|
(20,000 |
)
|
Accumulated
deficit
|
|
|
(6,952,074 |
)
|
|
|
(4,419,657 |
)
|
TOTAL
STOCKHOLDERS' DEFICIT
|
|
|
(996,983 |
)
|
|
|
(312,118 |
)
|
TOTAL
LIABILITIES ANDSTOCKHOLDERS'
DEFICIT
|
|
$ |
312,196 |
|
|
$ |
364,423 |
|
The
accompanying notes are an integral part of these condensed consolidated financial
statements.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
|
FOR
THE THREE MONTHS ENDED
|
|
|
FOR
THE NINE MONTHS ENDED
|
|
|
|
SEPTEMBER 30,
|
|
|
SEPTEMBER 30,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(UNAUDITED)
|
|
|
(UNAUDITED)
|
|
|
(UNAUDITED)
|
|
|
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SALES
|
|
$ |
40,241
|
|
|
$ |
10,433 |
|
|
$ |
119,280 |
|
|
$ |
94,994 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COSTOF
GOODS
SOLD
|
|
|
36,007 |
|
|
|
10,900 |
|
|
|
84,262 |
|
|
|
81,379 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GROSS
PROFIT
|
|
|
4,234 |
|
|
|
(467 |
)
|
|
|
35,018 |
|
|
|
13,615 |
|
OPERATING
EXPENSES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administrative expenses (including equity-based expenses
of $377,001, $0, $377,001 and $40,526, respectively)
|
|
|
601,502 |
|
|
|
724,615 |
|
|
|
852,741 |
|
|
|
976,656 |
|
Product
development costs (including equity-based
expenses of $0, $0, $1,470,551 and $0,
respectively)
|
|
|
- |
|
|
|
- |
|
|
|
1,470,551 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS
FROM OPERATIONS
|
|
|
(597,268 |
)
|
|
|
(725,082 |
)
|
|
|
(2,288,274 |
)
|
|
|
(963,041 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER
INCOME AND (EXPENSE)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
200 |
|
|
|
963 |
|
|
|
312 |
|
|
|
1,163 |
|
Interest
expense
|
|
|
(117,741 |
)
|
|
|
(13,366 |
)
|
|
|
(128,507 |
)
|
|
|
(46,147 |
)
|
Change
in fair value of derivative
liabilities
|
|
|
(111,148 |
)
|
|
|
- |
|
|
|
(111,148 |
)
|
|
|
- |
|
NET
OTHER
EXPENSE
|
|
|
(228,689 |
)
|
|
|
(12,403 |
)
|
|
|
(239,343 |
)
|
|
|
(44,984 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS
|
|
|
(825,957 |
)
|
|
|
(737,485 |
)
|
|
|
(2,527,617 |
)
|
|
|
(1,008,025 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PREFERRED
STOCK DIVIDEND
|
|
|
(1,600 |
)
|
|
|
(1,600 |
)
|
|
|
(4,800 |
)
|
|
|
(4,800 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LOSS
APPLICABLE TO COMMON
SHAREHOLDERS
|
|
$ |
(827,557 |
)
|
|
$ |
(739,085 |
)
|
|
$ |
(2,532,417 |
)
|
|
$ |
(1,012,825 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC
AND
DILUTED LOSS PERCOMMON
SHARE
|
|
$ |
(0.03 |
)
|
|
$ |
(0.04 |
)
|
|
$ |
(0.10 |
)
|
|
$ |
(0.06 |
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BASIC
AND
DILUTED WEIGHTED AVERAGE
SHARES
OUTSTANDING
|
|
|
27,510,740 |
|
|
|
19,983,251 |
|
|
|
25,595,631 |
|
|
|
16,631,410 |
|
The
accompanying notes are an integral part of these condensed consolidated
financial statements.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(UNAUDITED)
FOR
THE NINE MONTHS ENDED SEPTEMBER
30,
|
|
2007
|
|
|
2006
|
|
|
|
(UNAUDITED)
|
|
|
(UNAUDITED)
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
Net
loss
|
|
$ |
(2,527,617 |
)
|
|
$ |
(1,008,025 |
)
|
Adjustments
to reconcile net loss to cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
29,720 |
|
|
|
23,355 |
|
Bad
debt expense
|
|
|
(5,833 |
)
|
|
|
- |
|
Common
stock issued for services
|
|
|
1,847,552 |
|
|
|
674,238 |
|
Change
in fair value of derivative liabilities
|
|
|
111,148 |
|
|
|
- |
|
Accretion
of debt discounts
|
|
|
108,493 |
|
|
|
- |
|
Changes
in operating assets and liabilities
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
4,224 |
|
|
|
7,171 |
|
Inventory
|
|
|
30,213 |
|
|
|
(344,409 |
)
|
Accounts
payable
|
|
|
55,475 |
|
|
|
(54,427 |
)
|
Accrued
expenses
|
|
|
155,722 |
|
|
|
53,337 |
|
|
|
|
|
|
|
|
|
|
NET
CASHFROM
OPERATING ACTIVITIES
|
|
|
(190,903 |
)
|
|
|
(648,760 |
)
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
Purchases
of property and
equipment
|
|
|
(7,404 |
)
|
|
|
(752 |
)
|
|
|
|
|
|
|
|
|
|
NET
CASH
FROM INVESTING
ACTIVITIES
|
|
|
(7,404 |
)
|
|
|
(752 |
)
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Proceeds
from issuance of common stock, net
|
|
|
- |
|
|
|
891,019 |
|
Proceeds
from stockholder loans
|
|
|
37,000 |
|
|
|
73,852 |
|
Proceeds
from convertible debentures
|
|
|
160,000 |
|
|
|
- |
|
Payment
on note payable
|
|
|
- |
|
|
|
(267,852 |
)
|
|
|
|
|
|
|
|
|
|
NET
CASH
FROM FINANCING
ACTIVITIES
|
|
|
197,000 |
|
|
|
697,019 |
|
|
|
|
|
|
|
|
|
|
NET
INCREASE (DECREASE) IN CASH
|
|
|
(1,307 |
)
|
|
|
47,507 |
|
|
|
|
|
|
|
|
|
|
CASH
AT
BEGINNING OF PERIOD
|
|
|
9,768 |
|
|
|
1,384 |
|
|
|
|
|
|
|
|
|
|
CASH
AT
END
OF PERIOD
|
|
$ |
8,461
$ |
|
|
|
48,891 |
|
|
|
|
|
|
|
|
|
|
NON-
CASH INVESTING AND FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Accrual
of preferred stock dividends
|
|
$ |
4,800 |
|
|
$ |
4,800 |
|
Stock
issued for accrued legal services
|
|
$ |
-
|
|
|
$ |
40,526 |
|
Stock
issued for future services
|
|
$ |
- |
|
|
$ |
389,693 |
|
Stock
issued under subscription agreement
|
|
$ |
-
|
|
|
$ |
36,533 |
|
Payment
for services with convertible debenture
|
|
$ |
90,000 |
|
|
$ |
- |
|
The
accompanying notes are an integral part of these condensed consolidated
financial statements.
NOTES
TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE
1 -
BASIS OF PRESENTATION AND NATURE OF OPERATIONS
BASIS
OF
PRESENTATION - The condensed consolidated financial statements include the
accounts of Proton Laboratories, Inc., and its wholly owned subsidiary ("Proton"
or the "Company"). All significant inter-company transactions and balances
have
been eliminated in consolidation.
In
April
2004, the Company changed its name from BentleyCapitalCorp.com, Inc. to Proton
Laboratories, Inc. The Company's subsidiary also changed its name from Proton
Laboratories, Inc. to Water Science, Inc.
CONDENSED
FINANCIAL STATEMENTS - The accompanying unaudited condensed consolidated
financial statements are condensed and, therefore, do not include all
disclosures normally required by accounting principles generally accepted
in the
United States of America . These statements should be read in conjunction
with
the Company's annual financial statements included in the Company's December
31,
2006 Annual Report on Form 10-KSB. In particular, the Company's significant
accounting principles were presented as Note 1 to the consolidated financial
statements in that report. In the opinion of management, all adjustments
necessary for a fair presentation have been included in the accompanying
condensed consolidated financial statements and consist of only normal recurring
adjustments. The results of operations presented in the accompanying condensed
consolidated financial statements for the nine months ended September 30,
2007
are not necessarily indicative of the results that may be expected for the
full
year ending December 31, 2007 .
NATURE
OF
OPERATIONS - The Company's operations are located in Alameda , California
. The
core business of the Company consists of the sales and marketing of the
Company's industrial, environmental and residential systems throughout the
United States of America which alter the properties of water to produce
functional water. The Company acts as an exclusive importer and master
distributor of these products to various companies. Additionally, the Company
formulates intellectual properties under licensing agreements, supplies consumer
products, consults on projects utilizing functional water, facilitates between
manufacturer and industry and acts as educators on the benefits of functional
water.
USE
OF
ESTIMATES - The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and
liabilities and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
BASIC
AND
DILUTED LOSS PER COMMON SHARE - Basic loss per common share is calculated
by
dividing net loss by the weighted-average number of common shares outstanding.
Diluted loss per common share is calculated by dividing net loss by the
weighted-average number of Series A convertible preferred shares, 8% convertible
debenture and common shares outstanding to give effect to potentially issuable
common shares except during loss periods when those potentially issuable
shares
are anti-dilutive. Potential common shares from convertible preferred stock
and
the 8% convertible debenture have not been included as they are anti-dilutive.
CONVERTIBLE
DEBENTURES - The Company accounts for conversion options embedded in convertible
debentures in accordance with SFAS No. 133 "Accounting for Derivative
Instruments and Hedging Activities" ("SFAS 133") and Emerging Issues Task
Force
("EITF") 00-19, "Accounting for Derivative Financial Instruments Indexed
to, and
potentially settled in, a Company's Own Stock" ("EITF 00-19"). SFAS 133
generally requires companies to bifurcate conversion options embedded in
convertible notes from their host instruments and to account for them as
free
standing derivative financial instruments in accordance with EITF 00-19.
SFAS
133 provides for an exception to this rule when convertible notes, as
host instruments, are deemed to be conventional as that term is described
in the
implementation guidance under Appendix A to SFAS 133 and further clarified
in
EITF 05-2 "The Meaning of "Conventional Convertible Debt Instrument" in Issue
No. 00-19.
PROTON
LABORATORIES, INC.
NOTES
TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE
2 -
BUSINESS CONDITION
The
accompanying consolidated financial statements have been prepared in conformity
with accounting principles generally accepted in the United States of America
,
which contemplate continuation of the Company as a going concern. The Company
has incurred losses applicable to common shareholders of $2,532,417 for the
nine
months ended September 30, 2007 . For September 30, 2007 and December 31,
2006
the Company had working capital deficits of $887,021 and $251,472, respectively.
The Company has relied upon borrowings from related parties, proceeds from
convertible debentures and capital raised through the sales of common stock
to
fund operations.
The
Company is working towards raising additional public funds to expand its
marketing and revenues. In addition, the Company is working with its Canadian
business associates to identify institutional businesses to market various
disinfection applications based upon functional water, pending government
approval.
On
February 20, 2007 , the Board of Directors of Proton Laboratories, Inc. (the
"Company") ratified an exclusive Marketing, Distribution and Sales Agreement
("Marketing Agreement") and a Manufacturing and Packaging Agreement
("Manufacturing Agreement"), each made with Aqua Thirst, Inc. Through the
enactment of these agreements, the Company has been able to acquire what
is
views as key components necessary to strengthen its infrastructure for the
manufacturing, marketing and sales of its products and applications.
The
Company's ability to continue as a going concern is dependent upon its ability
to generate sufficient cash flows to meet its obligations on a timely basis,
to
obtain additional financing as may be required, and ultimately to attain
profitable operations. However, there is no assurance that profitable operations
or sufficient cash flows will occur in the future.
NOTE
3 -
CONVERTIBLE DEBTURE
On
June
29, 2007 , the Company entered into a financing arrangement with Legacy Media,
LLC ("Legacy") that provided the issuance of a $250,000, 8.0% convertible
debenture, due December 29, 2007 . Proceeds from the arrangement were received
in two installments of $125,000, net of $90,000 held as payment for services
by
Legacy, on July 6 and August 6, 2007 and has been used for operations. Upon
issuance, the convertible debenture is convertible into shares of the Company'
common stock, at the lesser of (i) 50% of the lowest closing bid price during
the fifteen (15) days of full trading prior to the conversion date or (ii)
100%
of the average of the five lowest closing bid prices for the thirty (30)
trading
days immediately following the first reverse split in the stock price. Legacy
also received an additional 3,200,000 shares for additional services rendered.
All of Legacy's shares may be registered in an SB-2 filing at their request,
subject to SEC approval. On October 4, 2007 , the Company filed an inital
registration statement for certain of Legacy's shares on form SB-2. Please
refer
to note 5.
PROTON
LABORATORIES, INC.
NOTES
TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In
connection with the issuance of the convertible debenture, the Company evaluated
the terms and features and determined that under EITF 05-2 "The Meaning of
Conventional Convertible Debt Instrument in Issue No. 00-19" the convertible
debt was deemed non-conventional due to the variable number of common shares
the
convertible debenture was convertible into. Accordingly, the conversion feature
embedded within the convertible debentures did not meet the established criteria
for equity classification under Emerging Issues Task Force EITF 00-19
"Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Company's Own Stock".
Upon
issuances, the Company valued the embedded conversion feature liability of
the
convertible debenture at $166,390 and $149,780 using the Black-Scholes valuation
method based on the following variables; a risk free rate of 5.10% and 4.52%;
an
exercise price of $0.09 and $0.075; a volatility of 151.4% and 147.5%; and
a
remaining term of 0.50 and 0.45 years, respectively. Since the fair value
of the
conversion feature exceeded the carrying value of the convertible debenture
on
the date of issuance, the Company recorded $66,170 of additional expense
during
the period ending September 30, 2007 . The Company is amortizing the discount
over the term of the convertible debenture. The embedded conversion feature
is
being carried at its respective fair value with changes in its value recorded
in
the statement of operations.
At
September 30, 2007 , the Company revalued the embedded conversion feature
liability of the convertible debenture at $361,148 resulting in an entry
to loss
on derivative liability of $44,978 during the three and nine month periods
ended
September 30, 2007 . The Company used the Black-Scholes valuation method
with
the following variables; risk free rate of 4.23%; exercise price of $0.03;
volatility of 159.9%; and a remaining life of 0.25 years.
During
the three and nine months ended September 30, 2007 , the Company amortized
$108,493 of the discount on the convertible debentures to interest expense.
To
date there have been no conversions.
NOTE
4 -
RELATED PARTY TRANSACTIONS
Stockholder
loans as of September 30, 2007 and December 31, 2006 consist of the following:
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
Note
payable to CEO and majority shareholder; principal and interest due
December 2009; interest is accrued at 7% per annum; unsecured.
|
|
$ |
287,642 |
|
|
$ |
270,642 |
|
|
|
|
|
|
|
|
|
|
Note
payable to shareholder; principal and
interest due December 2009; interest is accrued at 7% per annum;
unsecured.
|
|
|
20,000 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
TOTAL
STOCKHOLDER LOAN
|
|
|
307,642 |
|
|
|
270,642 |
|
|
|
|
|
|
|
|
|
|
Less:
Current Portion
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
TOTAL
STOCKHOLDER LOAN - LONG
TERM
|
|
$ |
307,642 |
|
|
$ |
270,642 |
|
PROTON
LABORATORIES, INC.
NOTES
TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
During
the nine months ended September 30, 2007 , two shareholders advanced the
Company
$37,000 at an interest rate of 7%. The $37,000 is included as a part of the
stockholder loans shown above. The Company did not make any payments on the
notes during the nine months ended September 30, 2007 .
During
the three and nine months ended September 30, 2007 , the Company accrued
$5,348
and $16,151, respectively, in interest expense on stockholder loans. , At
September 30, 2007 , the Company had accrued interest relating to stockholder
loans of $67,705 recorded in accrued liabilities on the accompanying balance
sheet.
During
the three and nine months ended September 30, 2007 , the Company accrued
$15,000
and $45,000, respectively, for salaries payable to the Company's Chief Executive
Officer, resulting in $260,233 of salaries payable recorded in accrued
liabilities on the accompanying balance sheet at September 30, 2007 .
NOTE
5 -
COMMON STOCK
During
January through September 30, 2007 the Company issued 7,612,300 shares of
common
stock for various services and agreements. The value of the shares was
$1,847,552 based on market prices ranging from $0.13 to $0.37 per share which
was the market price of the Company's common stock on the date of issuance.
NOTE
6 -
COMMITMENTS
PRODUCTION
AGREEMENT - In June 2005, the Company entered into an agreement with Mitachi,
a
Japanese electronics component manufacturer, to aid in the production of
enhanced drinking water generators. Pursuant to this agreement, Mitachi agreed
to pay the Company 25,000,000 Yen for engineering design, molding, tooling
and
preparation costs, and the exclusive product distribution rights for China
,
Taiwan , and Japan . As of September 30, 2007 , Mitachi had paid 6,000,000
Yen,
or $52,506, for the above mentioned distribution rights. Since the project
is
not yet completed and no units have been sold, this amount is classified
as
deferred revenue.
EQUITY
LINE - In June 2007, the Company terminated an equity line of credit agreement
with a private investment fund. No funds were drawn down on this equity line,
and no shares of stock were sold to the investment fund.
LEASE
COMMITMENT - On July 1, 2007 , the Company entered into a lease agreement
to pay
monthly lease payments of $3,852 until June 30, 2008 and $3,966 from July
1,
2009 through June 30, 2009 .
NOTE
7 -
SUBSEQUENT EVENT
On
October 5, 2007 , the Company issued 200,000 shares of common stock for legal
services rendered. The Company valued the shares at the closing price of
the
Company's common stock of $0.06 resulting in share based compensation of
$12,000
on the date of the transaction.
FORWARD-LOOKING
STATEMENT
Certain
statements contained herein, including, without imitation, statements containing
the words, "believes," "anticipates," "expects," and other words of similar
meaning, constitute "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements involve
known
and unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements, to be materially different from any
future
results, performance, or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, readers are cautioned
not
to place undue reliance on such forward-looking statements. In addition to
the
forward-looking statements contained herein, the following forward-looking
factors could cause our future results to differ materially our forward-looking
statements: competition, funding, government compliance and market acceptance
of
our products.
INTRODUCTION
The
following discussion and analysis of our financial condition and results
of
operations should be read in conjunction with our audited financial statements
and the accompanying notes thereto for the year ended December 31, 2006 which
appear in our Form 10-KSB for the year then ended, and our unaudited financial
statements for the three and nine months ended September 30, 2007 and the
accompanying notes thereto and the other financial information appearing
elsewhere herein.
The
accompanying consolidated financial statements have been prepared in conformity
with accounting principles generally accepted in the USA , which contemplates
our continuation as a going concern. We have incurred losses applicable to
common shareholders of $2,532,417 for the nine months ended September 30,
2007 .
We had working capital deficit of $887,021 at September 30, 2007 . Loans
and
equity funding were required to fund operations. We had a stockholder deficit
of
$996,983 at September 30, 2007 and a stockholders deficit of $312,118 at
December 31,2006.
Our
independent auditors made a going concern qualification in their report dated
April 13, 2007 , which raises substantial doubt about our ability to continue
as
a going concern. The financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts
or
amounts and classification of liabilities that might be necessary should
the
Company be unable to continue in existence. Our ability to continue as a
going
concern is dependent upon our ability to generate sufficient cash flows to
meet
our obligations on a timely basis, to obtain additional financing as may
be
required, and ultimately to attain profitable operations. However, there
is no
assurance that profitable operations or sufficient cash flows will occur
in the
future. We have our primary office located in Alameda , California . During
2006, we created a presence in Quincy , Washington and Portland , Oregon
by
aligning ourselves with office spaces that were made available to us. These
offices are used primarily for marketing and sales generation.
Our
business consists of the development, marketing and sales of the industrial,
environmental, and residential systems through the United States , which
alter
the properties of water to produce functional water. During 2006, we continued
to import and resell systems manufactured by various Japanese companies;
however, during the same time period the company started design, engineering,
parts sourcing and assembly identification for developing its own brand labeled
products. In Management's view, the company has successfully designed,
engineered and developed five commercial systems and one residential unit.
We
need to raise more funds to bring our residential counter top unit to market,
and there is no assurance that such funds can be raised. The Company believes
the food safety commercial unit will be ready for market introduction during
the
third quarter of 2007, following certification by an independent underwriters
laboratory. We are prioritizing the marketing and distribution of our food
safety commercial unit, which can also have applications in the medical,
dental
and sports facility industries.
We
formulate intellectual properties under licensing agreements; supply consumer
products; consult on projects utilizing functional water; facilitate usage,
uses
and users of functional water between manufacturer and industry; and act
as
educators on the benefits of functional water. Our business has been focused
on
marketing functional water equipment and systems. Alkaline-concentrated
functional water may have health-beneficial properties and may be used for
drinking and cooking purposes. Acidic-concentrated functional water may be
used
as a topical, astringent medium.
In
February 2007, the Company entered into an exclusive Marketing, Distribution
and
Sales Agreement and a Manufacturing and Packaging Agreement with Aqua Thirst,
Inc. These agreements effectively provide that the Company will have access
to
Aquathirst's product distribution channels in domestic and international
markets. These distribution channels will cover residential, cosmetic, medical,
agricultural, food processing and consumer product areas.
CRITICAL
ACCOUNTING POLICIES AND ESTIMATES
Our
discussion and analysis of our financial condition and results of operations
is
based upon our consolidated financial statements, which have been prepared
in
accordance with generally accepted accounting principles.
The
preparation of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenue
and
expenses, and related disclosure of contingent assets and liabilities. On
an
ongoing basis, we evaluate our estimates. We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable
under the circumstances. These estimates and assumptions provide a basis
for us
to make judgments about the carrying values of assets and liabilities that
are
not readily apparent from other sources. Our actual results may differ from
these estimates under different assumptions or conditions, and these differences
may be material.
We
recognize revenue when all four of the following criteria are met: (i)
persuasive evidence that an arrangement exists; (ii) delivery of the products
and/or services has occurred; (iii) the selling price is both fixed and
determinable and; (iv) collectibility is reasonably probable.
Our
revenues are derived from sales of our industrial, environmental and residential
systems, which alter the properties of water to produce functional water.
We
believe that this critical accounting policy affects our more significant
judgments and estimates used in the preparation of our consolidated financial
statements.
COMPARISON
OF THREE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
We
had
revenue of $40,241 for the three months ended September 30, 2007 compared
to
revenue of $10,433 for the three months ended September 30, 2006 . During
the
current period the Company is developing its new line of products, and thus
expects the revenue base will remain fairly consistent.
We
incurred a net loss of $825,957 for the three months ended September 30,
2007
and a net loss of $737,485 for the three months ended September 30, 2006
. This
was an increase in net loss attributable to the recording of non-cash interest
expense of $108,493 related to the amortization of the discount on the
convertible debentures and additional expense related to the change in the
fair
value of the derivative liabilities of $111,148 during the three months ended
September 30, 2007 .
COMPARISON
OF NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
We
had
revenue of $119,280 for the nine months ended September 30, 2007 compared
to
revenue of $94,994 for the nine months ended September 30, 2006 . During
the
current period the Company is developing its new line of products, and thus
expects the revenue base will remain fairly consistent.
We
incurred a net loss of $2,527,617 for the nine months ended September 30,
2007
and a net loss of $1,008,025 for the nine months ended September 30, 2006
. This
was an increase in net loss attributable to in-kind consultant compensation
expenses incurred in the sourcing of manufacturing, marketing and sales
infrastructure necessary for the Company. In addition, the Company had non-cash
interest expense of $108,493 related to the amortization of the discount
on the
convertible debentures and additional expense related to the change in the
fair
value of the derivative liabilities of $111,148 during the nine months ended
September 30, 2007 .
Cash
used
by operating activities was $190,903 for the nine months ended September
30,
2007 compared to cash used by operating activities of $648,760 for the nine
months ended September 30, 2006 . The increase is directly related to the
increase in the Company's net loss.
We
had
total assets at September 30, 2007 of $312,196, compared to $364,423 at December
31, 2006 . During the current period that the Company is developing its new
line
of products, and expects that the total asset base will remain fairly
consistent.
At
September 30, 2007 , we had cash on hand of $8,461. Our growth is dependent
on
our attaining profit from our operations and our raising of additional capital
either through the sale of stock or borrowing funds. There is no assurance
that
we will be able to raise any equity financing or sell any of our products
to
generate a profit.
At
September 30, 2007 , we owed stockholder loans of $307,642. In March 2007,
we
entered into an equity line of credit with a private investor. As of September
30, 2007 we terminated this equity line without draw down. In addition, during
the nine months ended we received $160,000 in net proceeds from the issuance
of
a convertible debenture which is due in December 2007.
FUTURE
CAPITAL REQUIREMENTS
Our
growth is dependent on attaining profit from our operations, or our raising
additional capital either through the sale of stock or borrowing. There is
no
assurance that we will be able to raise any equity financing or sell any
of our
products at a profit.
Our
future capital requirements will depend upon many factors, including:
-
- The
cost to acquire equipment that we then would resell.
-
- The
cost of sales and marketing.
-
- The
rate at which we expand our operations.
-
- The
results of our consulting business.
-
- The
response of competitors.
a) Evaluation
of disclosure controls and procedures.
Based
on
their evaluation of our disclosure controls and procedures (as defined in
Rule
13a-15e under the Securities Exchange Act of 1934), our principal executive
officer and principal financial officer have concluded that as of the end
of the
period covered by this quarterly report on Form 10-QSB such disclosure controls
and procedures were not effective to ensure that information required to
be
disclosed by us in reports that we file or submit under the Exchange Act
is
recorded, processed, summarized and reported within the time periods specified
in Securities and Exchange Commission rules and forms, because of certain
adjustments required by our auditors in the area of equity.
In
connection with its review of the Company's consolidated financial statements
for the quarter ended September 30, 2007, Hansen, Barnett & Maxwell
("HB&M"), the Company's registered public accounting firm, advised the Audit
Committee and management of internal control matters with respect to certain
financial reporting controls that they considered to be a material weakness,
which is described below. A material weakness is a control deficiency, or
a
combination of control deficiencies, that results in there being more than
a
remote likelihood that a material misstatement of the annual or interim
financial statements will not be prevented or detected. The material weakness
identified at September 30, 2007 was as follows:
A
material weakness existed in our control environment relating to inadequate
staffing of our technical accounting function, including a lack of sufficient
personnel with skills, training and familiarity with certain complex technical
accounting pronouncements that have or may affect our financial statements
and
disclosures.
In
response to the observations made by HB&M, we are in the process of
implementing enhancements to our internal controls, accounting staff and
procedures, which we believe address the matters raised by HB&M, including
the retaining of additional outside consultants and employees who will have
the
skills, training and familiarity with certain complex technical accounting
pronouncements appropriate to preparing our financial statements and
disclosures.
We
are in
the process of improving our internal controls in an effort to remediate
these
deficiencies. Our Chief Financial Officer has implemented revisions and
instituted certain checks and balances to our accounting system. Additionally,
he has addressed tighter controls over all aspects of financial revenue and
expense recognition, as well as improving supervision and training of our
accounting staff. We are continuing our efforts to enhance, improve and
strengthen our control processes and procedures. Our management and directors
will continue to work with our auditors and other outside advisors to ensure
that our controls and procedures are adequate and effective.
(b) Changes
in internal control over financial reporting.
During
the quarter under report, our Chief Financial Officer has implemented revisions
and instituted certain checks and balances to our accounting system.
Additionally, he continues to address tighter controls over all aspects of
financial revenue and expense recognition, as well as improving supervision
and
training of our accounting staff.
The
evaluation of our disclosure controls included a review of whether there
were
any significant deficiencies in the design or operation of such controls
and
procedures, material weaknesses in such controls and procedures, any corrective
actions taken with regard to such deficiencies and weaknesses and any fraud
involving management or other employees with a significant role in such controls
and procedures.
None.
During
July 2007, the Company entered into an agreement with Legacy Media, LLC in
connection with the agreement Legacy Media, LLC has been granted 3.2 million
shares of the Company's restricted common stock to provide investor relations
services.
During
July 2007, Legacy Media, LLC has also been issued a convertible debenture
by the
Company in the amount of $250,000, incurring interest at 8% and due in December
2007. The convertible debenture is convertible immediately into shares of
the
Company's common stock, at the lesser of (i) 50% of the lowest closing bid
price
during 15 days prior to conversion or (ii) 100% of the average of the five
lowest closing bid prices for 30 Trading Days immediately following any reverse
split in the common stock. All of Legacy Media, LLC's shares may be registered
in an SB-2 filing at its request, subject to SEC approval.
The
Company also issued 200,000 shares of restricted common stock to an independent
consultant for legal and business services rendered.
These
securities were issued in private transactions, in reliance on the exemption
available under Section 4(2) of the 1933 Act.
NONE.
No
matters were submitted to a vote of security holders during the quarter ended
September 30, 2007 .
Pursuant
to Section RCW 23B.07.040(b) of the Revised Code of Washington , a majority
of
the shareholders of Proton Laboratories, Inc. acting by a Shareholder Consent
in
Lieu of Annual Meeting have appointed a new Board of Directors as follows:
Edward Alexander , Don Gallego , Gregory Darragh , Jed
A. Astin , Gary Taylor and Steven Perry . Mr.
Miceal Ledwith has stepped down from the Board following good service.
The majority shareholders also consented to the amendment of the articles
of
incorporation to increase the number of Board Members to nine. They have
also
consented to the appointment of Dr. Kochiki Hanoaka to the Board
as soon as the amendment has been properly filed with the state of Washington
.
The
effective date of the consent is June 6, 2007 . Majority shareholder consents
were received as of July 27, 2007 . The total number of shareholder votes
in
favor of the consent was 16,279,308. Proton's total outstanding number of
shares
on the effective date of the consent was 29,185,673. A 14-C Statement will
be
filed with the Commission shortly.
NONE
In
accordance with the requirements of the Exchange Act, the registrant caused
this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PROTON
LABORATORIES, INC.
|
|
|
|
|
|
|
Date:
January 4, 2008
|
By:
|
/s/
Edward Alexander
|
|
|
EDWARD
ALEXANDER
|
|
|
Chief
Executive Officer, President,
|
|
|
Principal
Accounting officer and
|
|
|
Chief
Financial Officer
|